Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ST-246 · 2 trials · 2 indications
Subjects were administered a single, daily oral dose of ST-246 (400 or 600 mg)and changes in safety parameteres were monitored. Safety parameters included adverse events, vital signs, physical examinations, laboratory tests (hematology, blood chemistry, and urinalysis) and electrocardiograms. The DAIDS AE grading table is a list of common terms and severity (intensity) of parameters used to describe adverse events occurring in NIAID-sponsored clinical studies/trials.
Evaluated safety parameters included: 1. physical examination/vital signs 2. electrocardiograms (heart rate, PR interval, QRS duration, QT interval, and QTc Bazett) 3. laboratory safety tests (hematology, chemistry, urinalysis) 4. adverse events (AEs) For a)-c), statistical values (mean, standard deviation, median, minimum, maximum) and changes from baseline (Day 1 pre-dose) to each time-point, were compared to laboratory normal reference ranges. If values for a)-d) were a Grade 3 or higher (in DAIDS AE Table)and ST-246-related, they were considered severe and significant, respectively.
| Arm | Type | Description |
|---|---|---|
| ST-246 400 mg | EXPERIMENTAL | ST-246 400mg (2 x 200 mg Capsules) Orally Once Daily for 14 days |
| ST-246 600 mg | EXPERIMENTAL | ST-246 600 mg (3 x 200 mg Capsules) Orally Once Daily for 14 days |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo capsules, Orally Once Daily for 14 days |
| ST-246 | EXPERIMENTAL | 250 mg, 400 mg or 800 mg of ST-246 given once daily for 21 days |
| Name | Type | Description |
|---|---|---|
| ST-246 400 mg | DRUG | Capsules, 400 mg daily for 14 days |
| ST-246 600 mg | DRUG | Capsules, 600 mg daily for 14 days |
| Placebo | DRUG | Capsules, once daily for 14 days |
| ST-246 | DRUG | 250 mg, 400 mg or 800 mg capsules given once daily for 21 days |
Inclusion Criteria: 1. 18 - 75 yrs 2. Healthy volunteer 3. Ability to consent 4. Available for clinical follow-up for study 5. Not taking other medications 6. Adequate venous access 7. Using adequate birth control; negative pregnancy test 8. Able and willing to avoid alcohol for screening and study...